Citations

Clear

350 citation(s) found for "Stevens, S".

Exome sequencing directly implicates 68 genes in inflammatory bowel disease
Zhu, Ruifei , Zhang, Qian , Yuan, Kai , Zhang, Rui , Turvey, Alexandra K. , Stevens, Christine R , Ahmad, Tariq, Bernstein, Çharles N. , Bokemeyer, Bernd , Brooks, Johanne , Butterworth, Jeffrey, Clark, Katie, Cummings, F, Ennis, Sarah, Färkkilä, M, Faubion, William A. , Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Irving, Peter, Jarvis, Mark , Johnston, EL, Karlson, Elizabeth W, Kemp, Cheryl, Kennedy, Nick, Lees, Charlie, Lewis, James D. , Li, Andy, Louis, Édouard , McGovern, Dermot P.B., Oglesby, Arabis, Perez, Kate J, Pollok, R, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Sands, Bruce, Satsangi, Jack, Schreiber, Stefan, Selinger, Christian, Shedwell, Sophy, Silverberg, M, Singh, Salil, Steel, Alan, Uhlig, H, Verma, Ajay, Vermeire, Séverine , Weersma, Rinse K. , Xavier, Ramnik, Parkes, Miles, Rioux, John D. , Anderson, Carl A. , Raine, Tim , Uhlig, Holm H. , Fachal, Laura , Bernstein, Charles Noah , Bokemeyer, Bernd , Brant, Steven R , Cho, Judy H , Duerr, Richard H , Faubion, William , Franchimont, Denis , Franke, André , Kupcinskas, Juozas , Lamb, Christopher A , Lewis, James D , Loescher, Britt-Sabina , Louis, Edouard , McCauley, Jacob L , Moayyedi, Paul , Newberry, Rodney D , Palotie, Aarno V. , Pekow, Joel , Prescott, Natalie , Sabic, Ksenija , Sands, Bruce E , Silverberg, Mark S , Sokol, Harry , Vermeire, Séverine , Weersma, Rinse K , Xavier, Ramnik J , Yu, Mingrui , Rioux, John D , Daly, Mark J. , Huang, Hailiang , Anderson, Carl A , Raine, Tim , Zhang, Qian , Yuan, Kai , Stevens, Christine R. , Fachal, Laura , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , Ennis, Sarah A. , Färkkilâ, Martti , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Karlson, Elizabeth W. , Kennedy, Nicholas Alexander , Lees, Charlie W. , McCauley, Jacob L. , McGovern, Dermot P.B. , McLaughlin, John , Moayyedi, Paul , Moran, G , Newberry, Rodney D. , Pekow, Joel , Satsangi, Jack, Sazonovs, Aleksejs , Schreiber, Stefan , Selinger, Christian P. , Steed, Helen , Parkes, Miles , Zhang, Rui

Mayo Clinic

No container title available | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.08.26352648 | PMID 42180385 Get It

Abstract Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal tract whose genetic basis is only partly resolved because most risk variants identified by genome-wide association studies (GWAS) lie in non-coding regions, limiting direct gene assignment and biological interpretation 1,2 . Here we analysed whole-exome and whole-genome sequencing data from 86,213 IBD cases and 478,363 controls of European ancestry. We identified 68 IBD genes directly implicated by conditionally independent protein-coding associations across the allele frequency spectrum. Many newly implicated IBD genes are supported by orthogonal genomic or pleiotropic evidence, pointing to disease-related pathways and nominating targets with therapeutic relevance. We further identified allelic series and non-additive effects at key loci such as NOD2 and TYK2. These results show that large-scale sequencing can resolve disease genes and pathways that remain ambiguous from non-coding association alone, providing a more direct route from human genetics to biological insight and therapeutic hypotheses.
Preoperative Orbital Compliance as a Predictor for Outcomes of Fat Decompression in Thyroid Eye Disease
Shteyman, Amy , Gregerson, Celestine, Stevens, Shanlee, Tran, Ann Q. , Coombs, Allison, Tooley, Andrea A. , Kazim, Michael, Coombs, Allison V., Kazim, Michael

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | May 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/iop.0000000000003231 | PMID 42113591 Get It

Purpose: To determine the clinical utility of the assessment of preoperative orbital compliance in predicting the amount of postoperative proptosis reduction in patients with stable-phase thyroid eye disease who undergo orbital fat decompression surgery. Methods: A retrospective chart review was conducted of stable-phase thyroid eye disease patients who underwent orbital fat decompression by a single surgeon. Orbital compliance was measured preoperatively as axial globe displacement (in millimeters) using a Hertel exophthalmometer. Displacement ≥2.5 mm was classified as high compliance and <2.5 mm as low compliance. Radiographic thyroid eye disease type, preoperative proptosis, and intraoperative fat volume removed were recorded. Linear regression analysis determined whether orbital compliance independently predicted postoperative proptosis reduction. Levene’s test assessed variability between groups. Results: Forty-six orbits from 24 patients were included, 15 orbits with low compliance and 31 with high orbital compliance. Patients with high orbital compliance had a mean postoperative proptosis reduction of 3.19 mm (range 0.5–6.0 mm) while patients with low orbital compliance had a mean proptosis reduction of 2.67 mm (range 2.0–3.5 mm). On average, higher preoperative orbital compliance led to 0.959 mm greater proptosis reduction compared with low orbital compliance, when accounting for radiographic thyroid eye disease type and volume of fat removed intraoperatively ( p = 0.048). Variability in proptosis reduction was higher among the high orbital compliance group ( p = 0.00085). Conclusions: Higher preoperative orbital compliance results in greater proptosis reduction. However, patients with high orbital compliance have greater variability in proptosis reduction, suggesting that surgical outcomes are less predictable among these patients.
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma
McGuirk, Joseph P. , Ghobadi, Armin , Bachier, Carlos, Shaughnessy, Paul , Awan, Farrukh T. , Maakaron, Joseph E., Bishop, Michael R. , Ho, P. Joy , Tam, Constantine S., Dickinson, Michael J., Darrah, Justin , Ross, Ainsley, Williams, Leah M., Pan, Chenyi , Stevens, William N., Serwer, Laura, Nguyen, Thao, Terrett, Jonathan, Kalaitzidis, Demetrios, Ma, Anna, Xu, Huansheng, Benton, Mark, Weaver, Annie, Cohen, S, Awan, Farrukh T , Dickinson, Michael , Waller, Edmund K , Murthy, Hemant S , Maziarz, Richard Thomas , Cheah, Chan Yoon , Bishop, Michael Russell , McGuirk, Joseph , Ghobadi, Armin , Maakaron, Joseph E. , Dickinson, Michael , Waller, Edmund K. , Murthy, Hemant S. , Williams, Leah M. , Serwer, Laura , Terrett, Jonathan A. , Weaver, Alana M., Beaussant, Sarah cohen , Cheah, Chan Y.

Mayo Clinic

Blood Advances | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020123 | PMID 42085626 Get It

This multicenter, single-arm, phase 1/2 study evaluated the safety and efficacy of CD19-directed allogeneic chimeric-antigen-receptor (CAR) immunotherapy CTX110 in adult patients with relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (NHL). Patients received 1 or 2 treatment courses: standard lymphodepletion, followed by 1 CTX110 infusion at dose levels (DLs) 1-4 (3-60 × 107 CAR T-cells; dose escalation, N=32), or 2 infusions at DL4 on days 1 and 35 (cohort expansion, N=31). Primary endpoints in dose escalation and cohort expansion were incidence of dose-limiting toxicities and objective response rate, respectively. CTX110 was administered to 63 heavily pretreated patients: 59% primary refractory, 43% with ≥3 prior treatment lines. Among 57 patients whose first infusion was DL≥3, rates of objective and complete response (CR) were 65% and 39%, respectively. Among 22 patients achieving CR, 5 (23%) had ongoing CR at data cutoff, with 15-50 (median 34) months follow-up. The 2-infusion regimen appeared to prolong response duration compared to 1 infusion (hazard ratio 0.65). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were reported in 54% and 13% of treated patients, respectively, including 2 grade ≥3 cases each. The most common grade ≥3 adverse events were neutropenia (59%), and anemia and thrombocytopenia (35% each). Serious adverse events occurred in 32% of treated patients, including CRS (14%), ICANS (8%), and febrile neutropenia (6%). In this r/r NHL population, CTX110 was well-tolerated, resulting in clinically meaningful responses at DL≥3, with a second infusion demonstrating evidence of further clinical benefit. This trial (NCT04035434) was registered at www.clinicaltrials.gov.
Recurrent cross-reactivity between Candida tropicalis and Candida parapsilosis on the BIOFIRE FilmArray Blood Culture Identification 2 panel
Stevens, Ryan W, Wengenack, Nancy L. , Puumala, Emily , Wengenack, Nancy L , Stevens, Ryan W.

Mayo Clinic

Journal of Clinical Microbiology | April 30, 2026 | Volume: 64 | Issue: 6 | Pages: No page available

10.1128/jcm.00335-26 | PMID 42059605 Get It

Contemporary Use of Common Procedural Terminology (CPT) Codes for Surgical Management of Cerebellopontine Angle Tumors
Stevens, Shawn, Babu, Seilesh, Jeffery, Kuhn, Dinh, Christine, Link, Michael J, Roland, J Thomas, Driscoll, Colin LW, Dinh, Christine T. , Stevens, Shawn M. , Agrawal, Yuri , Link, Michael J., Driscoll, Colin L. W.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | April 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2790-6085 Get It

Abstract Cerebellopontine angle (CPA) tumors, including vestibular schwannomas (VS), often require microsurgical resection. These are typically surgical procedures performed by co-surgeons, and some controversy and confusion exist regarding use of common procedural terminology (CPT) codes for billing, given the American Medical Association (AMA) describes two distinct coding sets for such cases. This investigation endeavored to: (1) Comprehensively review all surgical coding options; (2) instruct on application; and (3) explore contemporary coding trends among surgeons. A multi-disciplinary task force (otologist/neurotologists and neurosurgeons) performed direct correspondence with various surgical societies, private consultancies, and the AMA. Survey instruments were distributed to active surgeons. Investigational period: 2022 to 2025. Survey instruments distributed at the 2023 American Neurotology Society (ANS) Fall Meeting. ANS, American Academy of Otolaryngology (AAO-HNSF), and the North American Skull Base Society (NASBS) representatives. Usage rate for CPT code sets (percentage of responders). Two CPT coding systems are currently accepted for surgical management of CPA tumors. The traditional/legacy codes (Indicator-2) allow use of co-surgery modifiers (-62). The newer approach/resection codes (skull base codes; Indicator-1) restrict modifier use. The history, application, and controversies surrounding the codes are detailed herein. About 40% of surgeons reported use of the traditional codes, while 45 to 49% use the skull base codes. Response rate was 31% of the active ANS membership in 2023. The AMA recognizes two CPT code sets for surgical management of CPA tumors. Both are appropriate, if properly applied. Contemporary surgeons likely utilize the sets in equal proportions.
Risk Factors for Developing Candidemia after Gastrointestinal Perforation and/or Ischemia and Its Outcomes: A Matched Case–Control Study
Kim, Myeongji , Barrett, Kemar O. , Mahmoud, Khalid H., Strajina, Veljko , Shah, Aditya, Molina Garcia, Sofia , Barrett, Kemar O , Ranganath, Nischal , Garcia, Sofia Molina , Stevens, Ryan W. , LeMahieu, Allison

Mayo Clinic

Surgical Infections | April 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10962964261445330 | PMID 42025448 Get It

Background: Candidemia is a serious complication after gastrointestinal (GI) perforation and/or ischemia, yet most evidence pools candidemia with intra-abdominal candidiasis (IAC). We sought candidemia-specific risk factors after GI perforation and/or ischemia and evaluated associated outcomes. Methods: We conducted a single-center, retrospective matched case–control study of adults undergoing emergency surgical procedure for GI perforation and/or ischemia and admitted to a surgical intensive care unit. Cases with candidemia during index admission were matched 4:1 to controls by age, Charlson Comorbidity Index, and surgical procedure year. Conditional logistic regression assessed pre-specified risk factors, and exploratory outcomes included mortality, length of stay, and days on invasive ventilation. Results: Twenty-four cases were matched to 99 controls. Factors identified to be independently associated with candidemia include the presence of IAC (adjusted OR [aOR]: 5.51, 95% CI: 1.61, 18.89; p = 0.007), upper GI injury (aOR: 4.28, 95% CI: 1.52–12.08; p = 0.006), and diffuse intra-abdominal contamination, compared with contained/none (aOR: 3.21, 95% CI: 1.06–9.74; p = 0.040). Among candidemia cases, species distribution was Candida albicans 41.7%, C. glabrata 33.3%, C. parapsilosis 12.5%, with single cases of C. tropicalis, C. krusei , and C. dubliniensis . Candidemia was associated with a longer hospital length of stay (+13.97 d; 95% CI: 0.90–27.04; p = 0.036), without significant differences in ICU stay, duration of invasive ventilation, or mortality. Conclusions: After GI perforation and/or ischemia, the risk of candidemia is highest in patients with upper GI injury and diffuse contamination, independent of IAC. These readily identifiable operative features may guide targeted surveillance and selective early antifungal strategies. Prospective validation is warranted.
A Retrospective, Comparative Cohort Analysis of the Utilization of Voriconazole-Containing Regimens Versus Itraconazole in the Treatment of Blastomycosis
Schanz, Caitlin , Rivera, Christina G. , Saleh, Omar M. Abu, Clement, Josh , Enzler, Mark J., Firkus, Danielle , Mara, Kristin C. , Vergidis, Paschalis , Stevens, Ryan W. , Schanz, Caitlin C , Mara, Kristin C , Vergidis, Paschalis , Rivera, Christina G , Stevens, Ryan W , Schanz, Caitlin C., Saleh, Omar Abu

Mayo Clinic

Journal of Fungi | April 14, 2026 | Volume: 12 | Issue: 4 | Pages: 279

10.3390/jof12040279 | PMID 42042373 Get It

Itraconazole is the recommended first-line antifungal agent in blastomycosis treatment. However, pharmacokinetic limitations and adverse drug events may necessitate the use of alternative antifungal agents. The primary objective of the study was to retrospectively describe a cohort of patients with blastomycosis who received voriconazole (as partial or complete therapy), for complete or partial treatment, compared to those who received itraconazole alone. Secondary objectives included rationale for voriconazole selection, treatment response, mortality, and adverse drug events. This retrospective multicenter cohort study included adult patients with proven/probable blastomycosis who received itraconazole or voriconazole. Treatment response was evaluated at one year or end of therapy, whichever came first. Mortality outcomes were assessed within 7 days of the last documented azole dose. Propensity score weighting and subgroup analysis were utilized to control confounding variables between cohorts. A total of 119 patients receiving itraconazole and 25 receiving voriconazole as complete or partial treatment were included. Voriconazole was often selected for CNS involvement or after intolerance to alternative azoles. After propensity score weighting, no significant difference in complete or partial treatment response was observed. Rates of all-cause mortality and blastomycosis-related mortality were numerically higher in the voriconazole cohort. Adverse drug event rates were similar between cohorts; however, discontinuation due to adverse events was more common in the voriconazole cohort. Voriconazole was most utilized for the treatment of blastomycosis in cases with CNS involvement or intolerance to other azoles. A statistically significant difference in response rate was not identified between voriconazole-containing or itraconazole-treated patients; however, given limited sample sizes, further data is needed to assess the equivalency of these agents in the treatment of blastomycosis.
Trends in Long-Duration Antibiotic Prescribing Following Focused Outpatient Antimicrobial Stewardship Efforts Across a Large Healthcare Enterprise
Ilges, Dan , Jensen, Kelsey , Draper, Evan , Thompson, E., Quillen, Jaxon , Hannan, Kellie Arensman, Ton, Angie , Prigge, Kimberly , Vergidis, Paschalis , Virk, Abinash, Hannan, Kellie N. Arensman , Arensman Hannan, Kellie , Ton, Angie Nu , Prigge, Kimberly A , Virk, Abinash , Stevens, Ryan W , Vergidis, Paschalis , Jensen, Kelsey , Ilges, Dan , Quillen, Jaxon K , Virk, Abinash , Stevens, Ryan W.

Mayo Clinic

Clinical Infectious Diseases | April 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag244 | PMID 41967093 Get It

Abstract Background Outpatient antibiotic stewardship programs (ASP) are recommended by the CDC and Joint Commission. We analyzed the impact of annual, focused syndrome-specific ASP interventions on trends in long-duration antibiotic prescribing (LDAP). Methods This was a retrospective, observational, multicenter cohort study from November 2020 through June 2025. All ambulatory encounters generating systemic antibiotic prescriptions within the healthcare enterprise were screened. Hospitalizations, emergency department visits, and infectious diseases encounters were excluded. Encounters generating ≥1 systemic antibiotic with &gt;7 days duration were categorized as long-duration. Targeted departments (primary and urgent care) received direct intervention (eg, education, peer-comparison reporting, data tracking). LDAP was modeled over time by month and compared by diagnosis group (ASP-priority diagnoses vs nonpriority) and provider specialty department (ASP-targeted vs nontargeted) using linear regression models. Results Of 642 579 encounters included, 42.2% were long duration. LDAP in ASP-targeted departments dropped from 46.8% to 34.8% (difference −12 percentage points [pp]), whereas nontargeted departments dropped from 45.5% to 39.1% (difference −6.4 pp). The estimated annual LDAP decrease was 3.4 pp in targeted versus 2.4 pp in nontargeted departments (difference 1.0 pp, P = .009). Within targeted departments, significant LDAP decreases were seen both in priority and nonpriority diagnoses, whereas nontargeted departments showed no change in LDAP in priority diagnoses. In a sensitivity analysis of nonpriority diagnoses, ASP-targeted departments had a larger estimated annual decrease in LDAP versus nontargeted (difference 1.4 pp, P &lt; .001). Conclusions Annual syndrome-specific ASP interventions correlated with improvements in LDAP, including outside of priority syndromes in targeted departments. LDAP is a viable metric for evaluating ambulatory ASPs.
Dr. Albert L. Rhoton Jr. and His Lasting Impact on Neurosurgery
Bauman, Megan M, Stevens, Baylee, Potes, Maria Astudillo , Michaelcheck, Charlotte E., Link, Michael J, Celda, María Peris, Graffeo, Chrisopher S, Gülsuna, Beste , Link, Michael J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 27, 2026 | Volume: 87 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1819366 Get It

Overview of 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on Group A Streptococcal (GAS) Pharyngitis: Risk Assessment Using Clinical Scoring Systems in Children and Adults
Barshak, Miriam B. , Linder, Jeffrey A., Watson, Michael E, Wessels, Michael R. , Carter, Danielle M, Cohen, Adam L, Bard, Jennifer Dien , Erdem, Güliz , Gregory, Christopher J. , Mochon, A Brian, Stevens, Ryan W, Kaur, Dipleen, Martin, Judith M. , Linder, Jeffrey A. , Watson, Michael E. , Martin, J M , Cohen, Adam L. , Kourtis, Athena P. , Martin, Judith M, Mochon, A. Brian, Shapiro, Daniel J. , Stevens, Ryan W.

Mayo Clinic

Clinical Infectious Diseases | February 12, 2026 | Volume: 82 | Issue: Supplement_3 | Pages: i92-i96

10.1093/cid/ciag098 | PMID 41692530 Get It

Abstract This publication represents the first part of an update to the clinical practice guideline on the diagnosis and management of group A streptococcal (GAS) pharyngitis, developed by the Infectious Diseases Society of America (IDSA). Diagnosis of GAS pharyngitis by clinician judgment alone is unreliable, and universal testing incurs cost and inconvenience for individuals at low risk of having GAS infection. Clinical scoring systems have been used to quantify the probability of a positive GAS throat culture based on standardized criteria such as the presence of fever, tonsillar enlargement or exudate, tender and enlarged anterior cervical lymph nodes, and the absence of cough. The goal of this manuscript is to review the evidence and provide a recommendation as to whether a scoring system should be used to decide which patients should have a GAS diagnostic test (ie, rapid antigen test [RADT], molecular method, and/or throat culture) performed. We performed a systematic review of randomized and nonrandomized studies that compared the use of a clinical scoring system to clinician judgment alone in predicting the result of a throat culture. Evidence from studies in children and adults suggests the diagnostic accuracy is comparable or slightly higher using a scoring system compared to clinician judgment alone. Although the studies are limited due to small size, lack of uniformity in outcome measures, and incomplete data, the consensus of the panel is that the balance of benefits and harms favors incorporation of a clinical scoring system as part of the evaluation of patients with sore throat and suspected GAS pharyngitis.